These promising findings in other cancers, together with our findings in the present study, lead us to suggest that the potential role of TM4SF1 and IGFBP3 as predictive biomarkers of response to vinflunine treatment in aUCC merits further study in a larger cohort of patients. The gene discussed is IGFBP3; the disease is cancer.